Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis

Authors: Nicole Trepanowski, MD, Rebecca M. Yim, BA, Rachel Wetstone, MPH, Elizabeth MacDonald, BS, Sarah Servattalab, MD, Subin Jacob-George, PA, John E. Harris, MD, PhD

Source: JAAD Case Reports, Vol 42, Iss , Pp 26-30 (2023)

Subject Terms: adverse effect, antibody, BMP6, bone morphogenetic protein 6, Dynein light chain Tctex-type 3, Dynlt3, Dermatology, RL1-803

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352512623003806; https://doaj.org/toc/2352-5126

Access URL: https://doaj.org/article/970c59f6f05341b483ee08942368a88c